AnaptysBio

ANAB55

$20.17arrow_drop_down2.55%-$0.53

ANAB55

$20.17

arrow_drop_down2.55%-$0.53

Performance History

Key Stats
Open	$20.76
Prev. Close	$20.75
EPS	-6.05
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	20.26	21.28
52 Week Range	13.36	41.30

Ratios







EPS	-6.05

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About AnaptysBio (ANAB)

AnaptysBio Inc (ANAB) is a biotechnology company that focuses on the discovery and development of therapeutic antibodies for the treatment of various diseases. The company's pipeline includes several product candidates targeting inflammatory disorders, autoimmune diseases, and immuno-oncology indications. ANAB's lead product candidate, etokimab, is being evaluated in multiple Phase 2 clinical trials for the treatment of moderate-to-severe atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic asthma.

ANAB's stock price history has been volatile over the past few years. In 2020, the stock reached a high of $131.25 and a low of $22.96. The stock price has since recovered and is currently trading around $80. ANAB's market capitalization is approximately $2.14 billion. The company's PEG ratio is not available at this time.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Daniel R. Faga
Headquarters: San Diego
Employees: 96
Exchange: NASDAQ

Keep an eye on AnaptysBio

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is AnaptysBio 's (ANAB) price per share?

The current price per share for AnaptysBio (ANAB) is $20.17. The stock has seen a price change of -$0.53 recently, indicating a -2.55% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for AnaptysBio (ANAB)?

For AnaptysBio (ANAB), the 52-week high is $41.31, which is 104.8% from the current price. The 52-week low is $13.36, the current price is 50.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is AnaptysBio (ANAB) a growth stock?

AnaptysBio (ANAB) has shown an average price growth of -3.55% over the past three years. It has received a score of 38 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying AnaptysBio as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is AnaptysBio (ANAB) stock price performance year to date (YTD)?

As of the latest data, AnaptysBio (ANAB) has a year-to-date price change of -7.05%. Over the past month, the stock has experienced a price change of -41.94%. Over the last three months, the change has been -41.79%. Over the past six months, the figure is -20.15%. Looking at a longer horizon, the five-year price change stands at 85.22%.

help

Is AnaptysBio (ANAB) a profitable company?

AnaptysBio (ANAB) has a net income of -$163.62M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 86.15% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -75.81% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $17.16M, with a revenue growth rate of 66.78%, providing insight into the company's sales performance and growth. The gross profit is $14.78M. Operating income is noted at -$164.41M. Furthermore, the EBITDA is -$139.45M.

help

What is the market capitalization of AnaptysBio (ANAB)?

AnaptysBio (ANAB) has a market capitalization of $613.75M. The average daily trading volume is 20.32, indicating the stock's liquidity and investor engagement.